U.S. Markets closed

Can The Uptrend Continue for Aurinia Pharmaceuticals (AUPH)?

Zacks Equity Research
Rise in loans, higher rates and increase in fee income support KeyCorp's (KEY) Q2 earnings.

Investors certainly have to be happy with Aurinia Pharmaceuticals Inc AUPH and its short term performance. After all, the stock has jumped by 12.2% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for AUPH?

While we can never know for sure, it is pretty encouraging that estimates for AUPH have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #1 (Strong Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks. You can see the complete list of today’s Zacks #1 Rank stocks here.

5 Trades Could Profit ""Big-League"" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.

See these buy recommendations now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Aurinia Pharmaceuticals Inc (AUPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research